AbbVie's Biosimilar Criticisms 'Lack Merit,' FDA Says
AbbVie Inc. misstated facts when it accused the U.S. Food and Drug Administration of unlawfully allowing biosimilars to use the same labels as their brand-name counterparts, the FDA said in a...To view the full article, register now.
Already a subscriber? Click here to view full article